Literature DB >> 33384952

Proteomic Analysis of Pre-Invasive Serous Lesions of the Endometrium and Fallopian Tube Reveals Their Metastatic Potential.

Mitchell Acland1, Georgia Arentz1, Max Mussared2, Fergus Whitehead3, Peter Hoffmann4, Manuela Klingler-Hoffmann4, Martin K Oehler4,5,6.   

Abstract

Serous endometrial cancer (SEC) and high grade serous ovarian cancer (HGSOC) are aggressive gynecological malignancies with high rates of metastasis and poor prognosis. Endometrial intraepithelial carcinoma (EIC), the precursor for SEC, and serous tubal intraepithelial carcinoma (STIC), believed to be the precursor lesion for HGSOC, can also be associated with intraabdominal spread. To provide insight into the etiology of these precancerous lesions and to explore the potential molecular mechanisms underlying their metastatic behavior, we performed a proteomic mass spectrometry analysis in a patient with synchronous EIC and STIC. Through histological and molecular identification of precancerous lesions followed by laser capture microdissection, we were able to identify over 450 proteins within the precancerous lesions and adjacent healthy tissue. The proteomic analysis of STIC and EIC showed remarkable overlap in the proteomic patterns, reflecting early neoplastic changes in proliferation, loss of polarity and attachment. Our proteomic analysis showed that both EIC and STIC, despite being regarded as premalignant lesions, have metastatic potential, which correlates with the common presentation of invasive serous gynecological malignancies at advanced stage.
Copyright © 2020 Acland, Arentz, Mussared, Whitehead, Hoffmann, Klingler-Hoffmann and Oehler.

Entities:  

Keywords:  endometrial intraepithelial carcinoma; high grade serous ovarian carcinoma; proteomics; serous endometrial carcinoma; serous tubal intraepithelial carcinoma

Year:  2020        PMID: 33384952      PMCID: PMC7771701          DOI: 10.3389/fonc.2020.523989

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  70 in total

Review 1.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

2.  The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma.

Authors:  Kuo-Chang Wen; Pi-Lin Sung; Yu-Ting Chou; Chih-Ming Pan; Peng-Hui Wang; Oscar Kuang-Sheng Lee; Cheng-Wen Wu
Journal:  Gynecol Oncol       Date:  2017-12-06       Impact factor: 5.482

3.  Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

Authors:  Rebecca T Marquez; Keith A Baggerly; Andrea P Patterson; Jinsong Liu; Russell Broaddus; Michael Frumovitz; Edward N Atkinson; David I Smith; Lynn Hartmann; David Fishman; Andrew Berchuck; Regina Whitaker; David M Gershenson; Gordon B Mills; Robert C Bast; Karen H Lu
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

4.  High-grade serous ovarian cancer arises from fallopian tube in a mouse model.

Authors:  Jaeyeon Kim; Donna M Coffey; Chad J Creighton; Zhifeng Yu; Shannon M Hawkins; Martin M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

5.  Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

Authors:  Mika A Sovak; Martee L Hensley; Jakob Dupont; Nicole Ishill; Kaled M Alektiar; Nadeem Abu-Rustum; Richard Barakat; Dennis S Chi; Paul Sabbatini; David R Spriggs; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2006-05-03       Impact factor: 5.482

6.  The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.

Authors:  R Yoshida; N Kimura; Y Harada; N Ohuchi
Journal:  Int J Oncol       Date:  2001-03       Impact factor: 5.650

Review 7.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

8.  The PRIDE database and related tools and resources in 2019: improving support for quantification data.

Authors:  Yasset Perez-Riverol; Attila Csordas; Jingwen Bai; Manuel Bernal-Llinares; Suresh Hewapathirana; Deepti J Kundu; Avinash Inuganti; Johannes Griss; Gerhard Mayer; Martin Eisenacher; Enrique Pérez; Julian Uszkoreit; Julianus Pfeuffer; Timo Sachsenberg; Sule Yilmaz; Shivani Tiwary; Jürgen Cox; Enrique Audain; Mathias Walzer; Andrew F Jarnuczak; Tobias Ternent; Alvis Brazma; Juan Antonio Vizcaíno
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

9.  Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.

Authors:  Mark A Eckert; Fabian Coscia; Agnieszka Chryplewicz; Jae Won Chang; Kyle M Hernandez; Shawn Pan; Samantha M Tienda; Dominik A Nahotko; Gang Li; Ivana Blaženović; Ricardo R Lastra; Marion Curtis; S Diane Yamada; Ruth Perets; Stephanie M McGregor; Jorge Andrade; Oliver Fiehn; Raymond E Moellering; Matthias Mann; Ernst Lengyel
Journal:  Nature       Date:  2019-05-01       Impact factor: 49.962

10.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Authors:  C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more
  1 in total

1.  A Protocol for the Acquisition of Comprehensive Proteomics Data from Single Cases Using Formalin-Fixed Paraffin Embedded Sections.

Authors:  Mitchell Acland; Parul Mittal; Georgia Arentz; Fergus Whitehead; Peter Hoffmann; Manuela Klingler-Hoffmann; Martin K Oehler
Journal:  Methods Protoc       Date:  2022-07-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.